CASGEVY Trademark

Trademark Overview

On Thursday, October 28, 2021, a trademark application was filed for CASGEVY with the United States Patent and Trademark Office. The USPTO has given the CASGEVY trademark a serial number of 97096682. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Wednesday, March 20, 2024. This trademark is owned by Vertex Pharmaceuticals Incorporated. The CASGEVY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations primarily comprising cells for the treatment of sickle cell disease; Pharmaceutical preparations primarily comprising cells for the treatment of beta thalassemia
casgevy

General Information

Serial Number97096682
Word MarkCASGEVY
Filing DateThursday, October 28, 2021
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateWednesday, March 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 20, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of blood disorders; Pharmaceutical preparations primarily comprising cells for the treatment of sickle cell disease; Pharmaceutical preparations primarily comprising cells for the treatment of beta thalassemia

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, November 9, 2021
Primary Code005
First Use Anywhere DateThursday, November 16, 2023
First Use In Commerce DateFriday, December 8, 2023

Trademark Owner History

Party NameVertex Pharmaceuticals Incorporated
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBoston, MA 02210
Party NameVertex Pharmaceuticals Incorporated
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02210

Trademark Events

Event DateEvent Description
Thursday, March 21, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, March 20, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Monday, March 4, 2024STATEMENT OF USE PROCESSING COMPLETE
Monday, February 12, 2024USE AMENDMENT FILED
Monday, March 4, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, February 12, 2024TEAS STATEMENT OF USE RECEIVED
Wednesday, November 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 13, 2023SOU EXTENSION 2 GRANTED
Monday, November 13, 2023SOU EXTENSION 2 FILED
Monday, November 13, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, May 3, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 1, 2023SOU EXTENSION 1 GRANTED
Monday, May 1, 2023SOU EXTENSION 1 FILED
Monday, May 1, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 30, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 30, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, November 30, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 30, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, November 15, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 20, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 20, 2022PUBLISHED FOR OPPOSITION
Wednesday, August 31, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, August 15, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, August 8, 2022ASSIGNED TO EXAMINER
Sunday, April 10, 2022TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Sunday, April 10, 2022TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, November 9, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, November 1, 2021NEW APPLICATION ENTERED

Related Keywords

casgevy pharmaceutical treatment preparations cells primarily comprising beta thalassemia disease cell